Shin Poong announces British NICE’s recommendation on Inisia Tab as primary therapy

Shin Poong Pharm(CEO Jae-Man Yoo) announced the National Institute for Health and Clinical Excellence(NICE), a drug cost-efficacy assessment agency under the British government, recommended the national health insurance benefit of the world’s first fibroids treatment ‘Inisia Tab(generic name: ulipristal acetate, European product name: Esmya)’ as a primary non-surgical therapy.

The NICE recomm...